Focal segmental glomerulosclerosis (FSGS) MedDRA version: 20.0 Level: PT Classification code 10067757 Term: Focal segmental glomerulosclerosis System Organ Class: 10038359 - Renal and urinary disorders
Conditions
Interventions
Product Name: Sparsentan
Product Code: RE-021
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Sparsentan
CAS Number: 254740-64-2
Current Sponsor code: RE-021
Other descriptive name: SPARSENTAN
Sponsors
Retrophin, Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patient or parent/legal guardian (as appropriate) is willing and able to provide signed informed consent, and where required, the patient is willing to provide assent, prior to any screening procedures. 2. The patient has biopsy-proven primary FSGS or documentation of a genetic mutation in a podocyte protein associated with FSGS. The biopsy may have been performed at any time in the past, but will preferably include electron microscopy (EM) and immunofluorescence (IF) characteristics consistent with primary FSGS. The patient may be enrolled based on light microscopy diagnosis of FSGS in the absence of EM and/or IF analysis, provided the history (nephrotic syndrome with hypoalbuminemia, treatment with immunosuppression) and the course of the disease are indicative of primary FSGS, and potential secondary causes captured by the exclusion criteria have been carefully ruled out. 3. Sites within the US: The patient is male or female aged 8 to 75 years, inclusive. Sites outside the US: The patient is male or female aged 18 to 75 years, inclusive. 4. The patient has a UP/C =1.5 g/g at screening. 5. The patient has an eGFR =30 mL/min/1.73 m2 at screening. 6. The patient has a mean seated blood pressure =100/60 mmHg (on a maximum of 2 antihypertensive treatments at screening, including RAAS inhibitors) and =160/100 mmHg (patients >18 years of age) or =90/60 mmHg and = the 95th percentile for age, sex, and height (patients =18 years of age). 7. Sexually active women of childbearing potential (WOCBP) must agree to the simultaneous use of 2 medically accepted methods of contraception from Day 1/Randomization until 90 days after the last dose of study medication. At least one method of contraception must be highly reliable (ie, can achieve a failure rate of 40 mIU/mL. All WOCBP must have a negative pregnancy test (urine, with positive results confirmed by serum) at Visits 1 and 3 (Screening and Day 1/Randomization). NOTE: Prior to menarche, pregnancy testing and contraceptive use is not required. However, the patient and their parent/guardian must be advised that, immediately upon menarche, the patient will be required to begin pregnancy testing and, if deemed necessary by the Investigator, initiate contraceptive use. This requirement cannot be avoided. 8. Males must be surgically sterile (more than 3 months post-vasectomy) or must agree to the use of medically accepted methods of contraception that are considered highly reliable from Day 1/Randomization until 90 days after the last dose of study medication. Are the trial subjects under 18? yes Number of subjects for this age range: 60 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this
Exclusion criteria
Exclusion criteria: 1. The patient has FSGS secondary to another condition. 2. The patient has positive findings on any of the following serological tests of primary or secondary glomerular injury: anti-nuclear antibody, anti-double stranded deoxyribonucleic acid (DNA) antibodies, anti-neutrophil cytoplasmic antibody, rheumatoid factor, anti-glomerular basement membrane antibodies, polyclonal antibodies identified by serum and urine protein electrophoresis, cryoglobulins, or kappa and lambda chains. 3. The patient has an indicator of relapse from complete remission (ie, recurrence or new occurrence of proteinuria >3.5 g/24 hours or UP/C >3.5 g/g within 30 days prior to or during screening). 4. The patient has a history of type 1 diabetes mellitus, uncontrolled type 2 diabetes mellitus (hemoglobin A1c [HbA1c] >8%), or nonfasting blood glucose >180 mg/dL at screening. 5. The patient has undergone any organ transplantation, with the exception of corneal transplants. 6. The patient requires any of the prohibited concomitant medications. 7. The patient has been treated with rituximab, cyclophosphamide, or abatacept within =3 months prior to screening. If a patient is taking other chronic immunosuppressive medications, the dosage must be stable for =1 month prior to randomization. 8. The patient has a documented history of heart failure (New York Heart Association Class II-IV) and/or previous hospitalization for heart failure or unexplained dyspnea, orthopnea, paroxysmal nocturnal dyspnea, ascites, and/or peripheral edema. 9. The patient has clinically significant cerebrovascular disease (transient ischemic attack or stroke) and/or coronary artery disease (hospitalization for myocardial infarction or unstable angina, new onset of angina with positive functional tests, coronary angiogram revealing stenosis, or a coronary revascularization procedure) within 6 months prior to screening. 10. The patient has hemodynamically significant valvular disease. 11. The patient has jaundice, hepatitis, or known hepatobiliary disease (including asymptomatic cholelithiasis), or alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >2 times the upper limit of the normal range at screening. 12. The patient is positive at screening for the human immunodeficiency virus (HIV) or markers indicating acute or chronic hepatitis B (HBV) infection (acute HBV is defined as a positive hepatitis B surface antigen [HBsAg], hepatitis B “e” antigen [HBeAg], HBV DNA in blood or liver, or immunoglobulin M [IgM] hepatitis B core antibody; chronic HBV is defined as a positive HBsAg and/or HBeAg and/or HBV DNA) or hepatitis C virus (HCV) infection (defined as reactive anti-HCV antibody and/or HCV RNA). 13. The patient has a history of malignancy other than adequately treated basal cell or squamous cell skin cancer or cervical carcinoma within the past 2 years. 14. The patient has a screening hematocrit value 5.5 mEq/L. 16. The patient is >18 years of age with a body mass index (BMI) >40, or is =18 years of age with a BMI in the 99th percentile plus 5 units at screening. 17. The patient has a history of alcohol or illicit drug use disorder (as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition), or a reported habitual alcohol intake greater than 21 units/week within 2 years prior to screening. 18. The patient has a history of serious side effect or allergic response t
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The efficacy objective of the study is to determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary FSGS. The safety objective of the study is to assess the safety and tolerability of sparsentan by double-blind monitoring of safety endpoints.;Secondary Objective: Not applicable;Primary end point(s): Efficacy End points: The primary efficacy endpoint is the slope of eGFR assessed at the final analysis. The surrogate efficacy endpoint is the proportion of patients achieving a Up/C =1.5 g/g and a >40% reduction from baseline in Up/C at Week 36. Safety End points: • Changes from baseline in body weight, vital signs, physical examinations, peripheral edema, 12-lead electrocardiogram (ECG), and clinical laboratory parameters • Changes from baseline in lipid profile (total cholesterol and triglycerides, low density lipoprotein cholesterol [LDL-C], very low-density lipoprotein cholesterol [VLDL-C] and triglycerides [VLDL-TG], and high-density lipoprotein cholesterol [HDL]) • Changes from baseline in serum albumin and serum potassium at each visit • The incidence of treatment-emergent adverse events (TEAEs);Timepoint(s) of evaluation of this end point: Primary efficacy and safety endpoints will be evaluated at the final analysis (Week 108) Surrogate efficacy analysis at Week 36 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Secondary efficacy endpoints include: • The percent change from Week 6 in eGFR at Week 108 • The percent change from baseline in Up/C at Week 36 assessed at the final analysis Other Efficacy Endpoints: • The absolute and percent change from baseline in eGFR at each visit • The percent change from Week 6 in eGFR at each visit • The proportion of patients achieving a Up/C =1.5 g/g and a >40% reduction from baseline in Up/C at each visit • The percent change from baseline in Up/C at each visit • The time to achieve the target reduction in Up/C (ie, =1.5 g/g and a >40% reduction) • The proportion of patients reaching a confirmed 40% change in eGFR, end-stage renal disease (ESRD), or death. (ESRD is defined as initiation of renal replacement therapy [RRT], kidney transplantation, or sustained eGFR 3.5 g/g) in patients who have achieved the target reduction in Up/C (ie, =1.5 g/g and a >40% reduction) at any time during the study • Changes from baseline in blood pressure at each visit • The proportion of patients requiring intensification in immunosuppressive medication during the study • The proportion of patients undergoing reduction in immunosuppressive medication during the study • Changes from baseline in quality of life (QOL), measured via patient-reported outcome (PRO) at each visit beginning with Week 12;Timepoint(s) of evaluation of this end point: Secondary endpoints will be assessed at the final analysis (Week 108) | — |
Countries
Australia, Canada, Czech Republic, Denmark, France, Germany, Hungary, Italy, Korea, Republic of, Poland, South Africa, Spain, Taiwan, United Kingdom, United States
Contacts
Public ContactRetrophin Call Center
Retrophin, Inc.
Outcome results
None listed